Related Experiment Video

Updated: May 11, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Novel pharmacotherapies of familial hyperlipidemia

Maria Drakopoulou1, Konstantinos Toutouzas, Christodoulos Stefanadis

  • 11st Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.

Pharmacology & Therapeutics
|May 4, 2013
PubMed

Insights

Familial hyperlipidemia causes high blood lipid levels, increasing cardiovascular disease risk. New therapies are in development to effectively lower LDL-cholesterol when conventional treatments fall short.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Pharmacology

Background:

  • Familial hyperlipidemia is an inherited condition causing elevated blood lipids.
  • Current therapies often fail to reach target LDL-cholesterol levels, contributing to cardiovascular disease.
  • There is a need for novel therapeutic strategies for this high-risk population.

Purpose of the Study:

  • To review emerging lipid-lowering therapies for familial hyperlipidemia.
  • To provide an overview of treatments in clinical development.
  • To identify alternative or adjunctive options for patients with uncontrolled LDL-cholesterol.

Main Methods:

  • Literature review of recent clinical studies and development pipelines.
  • Analysis of novel therapeutic targets and mechanisms of action.
  • Synthesis of data on efficacy and safety of emerging treatments.

Main Results:

  • Several new classes of lipid-lowering agents are in clinical development.
  • These novel therapies target different pathways to reduce LDL-cholesterol.
  • Promising results suggest potential for improved efficacy in high-risk patients.

Conclusions:

  • Emerging therapies offer new hope for managing familial hyperlipidemia.
  • These treatments may provide effective alternatives or additions to current standards of care.
  • Further research and clinical trials are essential to establish their role in cardiovascular disease prevention.

Keywords:
ApolipoproteinB inhibitorsCholesterol ester transfer protein inhibitorsFamilial hypercholesterolemiaHDL-CLDL-CLDL-lowering therapyMTPMicrosomal triglyceride transfer protein inhibitorsPCSK9Protein convertase subtilisin/kexin type 9 inhibitorshigh-density lipoprotein cholesterollow-density lipoprotein cholesterolmicrosomal triglyceride transfer proteinprotein convertasesubtilisin/kexin type 9

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...